• +1-646-491-9876
    • +91-20-67278686

    Search

    Irritable Bowel Syndrome Pipeline Review H1 2017

    Irritable Bowel Syndrome Pipeline Review H1 2017

    • Report Code ID: RW0001799309
    • Category Pharmaceuticals
    • No. of Pages 148
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Irritable Bowel Syndrome - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Irritable Bowel Syndrome - Pipeline Review, H1 2017, provides an overview of the Irritable Bowel Syndrome (Gastrointestinal) pipeline landscape.

    Inflammatory Bowel Diseases (IBD) is a broad term that describes conditions with chronic or recurring immune response and inflammation of the gastrointestinal tract. Signs and symptoms include abdominal cramps and pain, diarrhea that may be bloody, weight loss, loss of appetite and fever. The predisposing factors include age, family history, smoking and some pain killers. Treatment includes corticosteroids, immune suppressors, antibiotics and pain relievers.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Irritable Bowel Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Irritable Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 12, 7, 11 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

    Irritable Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome (Gastrointestinal) .
    - The pipeline guide reviews pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Irritable Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Irritable Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Irritable Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    List of Tables 5
    List of Figures 6
    Introduction 7
    Publisher Report Coverage 7
    Irritable Bowel Syndrome - Overview 8
    Irritable Bowel Syndrome - Therapeutics Development 9
    Pipeline Overview 9
    Pipeline by Companies 10
    Pipeline by Universities/Institutes 13
    Products under Development by Companies 14
    Products under Development by Universities/Institutes 16
    Irritable Bowel Syndrome - Therapeutics Assessment 17
    Assessment by Target 17
    Assessment by Mechanism of Action 20
    Assessment by Route of Administration 23
    Assessment by Molecule Type 25
    Irritable Bowel Syndrome - Companies Involved in Therapeutics Development 27
    4D Pharma PLC 27
    A. Menarini Industrie Farmaceutiche Riunite Srl 27
    Alfa Wassermann SpA 28
    Allergan Plc 28
    Ardelyx Inc 29
    Astellas Pharma Inc 29
    CJ HealthCare Corp 30
    ConSynance Therapeutics Inc 30
    Cosmo Pharmaceuticals NV 31
    Dong-A ST Co., Ltd. 31
    Eisai Co Ltd 32
    Enterome Bioscience SA 32
    GlaxoSmithKline Plc 33
    Innovative Med Concepts LLC 33
    Ironwood Pharmaceuticals Inc 34
    Kissei Pharmaceutical Co Ltd 35
    Lexicon Pharmaceuticals Inc 35
    Napo Pharmaceuticals Inc 36
    Pfizer Inc 36
    RaQualia Pharma Inc 37
    RedHill Biopharma Ltd 37
    SK Biopharmaceuticals Co Ltd 38
    Sumitomo Dainippon Pharma Co Ltd 38
    Synergy Pharmaceuticals Inc 39
    Synthetic Biologics Inc 39
    Vitality Biopharma Inc 40
    Irritable Bowel Syndrome - Drug Profiles 41
    (celecoxib + famciclovir) - Drug Profile 41
    ASP-7147 - Drug Profile 43
    bedoradrine sulfate - Drug Profile 44
    Biologic for Irritable Bowel Syndrome with Constipation - Drug Profile 47
    Biologic for Irritable Bowel Syndrome with Diarrhea - Drug Profile 48
    Blautix - Drug Profile 49
    Canchew Plus - Drug Profile 51
    CJ-14199 - Drug Profile 52
    crofelemer DR - Drug Profile 53
    CSTI-300 - Drug Profile 57
    DA-6886 - Drug Profile 58
    Drugs for Irritable Bowel Syndrome with Diarrhea - Drug Profile 59
    DSP-6952 - Drug Profile 60
    E-2508 - Drug Profile 61
    EB-420 - Drug Profile 62
    GSK-3179106 - Drug Profile 63
    ibodutant - Drug Profile 64
    linaclotide - Drug Profile 65
    linaclotide DR1 - Drug Profile 73
    linaclotide DR2 - Drug Profile 74
    lovastatin - Drug Profile 75
    LT-4006 - Drug Profile 79
    LX-1033 - Drug Profile 80
    ondansetron hydrochloride CR - Drug Profile 82
    ORP-101 - Drug Profile 88
    PBF-677 - Drug Profile 89
    plecanatide - Drug Profile 90
    PR-38 - Drug Profile 99
    pregabalin - Drug Profile 100
    relenopride hydrochloride - Drug Profile 105
    rifamycin CR - Drug Profile 107
    rifaximin - Drug Profile 110
    RQ-00202730 - Drug Profile 114
    RQ-00310941 - Drug Profile 115
    Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine - Drug Profile 116
    solabegron hydrochloride - Drug Profile 117
    tenapanor hydrochloride - Drug Profile 120
    VB-210 - Drug Profile 125
    Irritable Bowel Syndrome - Dormant Projects 126
    Irritable Bowel Syndrome - Discontinued Products 129
    Irritable Bowel Syndrome - Product Development Milestones 130
    Featured News & Press Releases 130
    Appendix 145
    Methodology 145
    Coverage 145
    Secondary Research 145
    Primary Research 145
    Expert Panel Validation 145
    Contact Us 145
    Disclaimer 146

    List of Tables

    Number of Products under Development for Irritable Bowel Syndrome, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Irritable Bowel Syndrome - Pipeline by 4D Pharma PLC, H1 2017
    Irritable Bowel Syndrome - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2017
    Irritable Bowel Syndrome - Pipeline by Alfa Wassermann SpA, H1 2017
    Irritable Bowel Syndrome - Pipeline by Allergan Plc, H1 2017
    Irritable Bowel Syndrome - Pipeline by Ardelyx Inc, H1 2017
    Irritable Bowel Syndrome - Pipeline by Astellas Pharma Inc, H1 2017
    Irritable Bowel Syndrome - Pipeline by CJ HealthCare Corp, H1 2017
    Irritable Bowel Syndrome - Pipeline by ConSynance Therapeutics Inc, H1 2017
    Irritable Bowel Syndrome - Pipeline by Cosmo Pharmaceuticals NV, H1 2017
    Irritable Bowel Syndrome - Pipeline by Dong-A ST Co., Ltd., H1 2017
    Irritable Bowel Syndrome - Pipeline by Eisai Co Ltd, H1 2017
    Irritable Bowel Syndrome - Pipeline by Enterome Bioscience SA, H1 2017
    Irritable Bowel Syndrome - Pipeline by GlaxoSmithKline Plc, H1 2017
    Irritable Bowel Syndrome - Pipeline by Innovative Med Concepts LLC, H1 2017
    Irritable Bowel Syndrome - Pipeline by Ironwood Pharmaceuticals Inc, H1 2017
    Irritable Bowel Syndrome - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017
    Irritable Bowel Syndrome - Pipeline by Lexicon Pharmaceuticals Inc, H1 2017
    Irritable Bowel Syndrome - Pipeline by Napo Pharmaceuticals Inc, H1 2017
    Irritable Bowel Syndrome - Pipeline by Pfizer Inc, H1 2017
    Irritable Bowel Syndrome - Pipeline by RaQualia Pharma Inc, H1 2017
    Irritable Bowel Syndrome - Pipeline by RedHill Biopharma Ltd, H1 2017
    Irritable Bowel Syndrome - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017
    Irritable Bowel Syndrome - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
    Irritable Bowel Syndrome - Pipeline by Synergy Pharmaceuticals Inc, H1 2017
    Irritable Bowel Syndrome - Pipeline by Synthetic Biologics Inc, H1 2017
    Irritable Bowel Syndrome - Pipeline by Vitality Biopharma Inc, H1 2017
    Irritable Bowel Syndrome - Dormant Projects, H1 2017
    Irritable Bowel Syndrome - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Irritable Bowel Syndrome - Dormant Projects, H1 2017 (Contd..2) , H1 2017
    Irritable Bowel Syndrome - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Irritable Bowel Syndrome, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    4D Pharma PLC
    A. Menarini Industrie Farmaceutiche Riunite Srl
    Alfa Wassermann SpA
    Allergan Plc
    Ardelyx Inc
    Astellas Pharma Inc
    CJ HealthCare Corp
    ConSynance Therapeutics Inc
    Cosmo Pharmaceuticals NV
    Dong-A ST Co., Ltd.
    Eisai Co Ltd
    Enterome Bioscience SA
    GlaxoSmithKline Plc
    Innovative Med Concepts LLC
    Ironwood Pharmaceuticals Inc
    Kissei Pharmaceutical Co Ltd
    Lexicon Pharmaceuticals Inc
    Napo Pharmaceuticals Inc
    Pfizer Inc
    RaQualia Pharma Inc
    RedHill Biopharma Ltd
    SK Biopharmaceuticals Co Ltd
    Sumitomo Dainippon Pharma Co Ltd
    Synergy Pharmaceuticals Inc
    Synthetic Biologics Inc
    Vitality Biopharma Inc

    Request for Sample

    Report Url http://www.reportsweb.com//irritable-bowel-syndrome-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//irritable-bowel-syndrome-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//irritable-bowel-syndrome-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments